MYOD1 and prostate cancer: BRCA2, DAB2IP, and the DNA-PKcs inhibitor NU7441 are prostate cancer-related markers, while the methylation of ESR1 and MYOD1 and expression of SEPT9 correlate with radiotherapy response in cervical cancer.